Son leads Arlington Capital Partners into Zhang's Everest Clinical Research Corp.
Arlington Capital Partners’ Erica Son is involved in the firm’s purchase of a contract research organization whose founder and CEO is Irene Zhang. Terms of Arlington’s majority investment in Everest Clinical Research Corp. were not disclosed. Irene and the other company executives will continue to lead the Toronto company.
Founded in 2004, Everest employs more than 300 and provides a suite of clinical research services to the pharmaceutical, biotechnology, and medical device industries across Phase I-IV trials.
In a statement, Erica said Arlington has been “very impressed” by Everest’s “long track record of outstanding bookings and backlog growth, both of which have grown consistently with new and existing customers through the ongoing COVID-19 pandemic.
Erica is also on the boards of Forged Solutions Group and Tex Tech Industries. She joined Arlington in 2017 from Thomas H. Lee Partners.
Arlington is currently investing out of its $1.7 billion fifth fund. The Washington private equity firm has $4 billion of committed capital and focuses on such industries as aerospace and defense; government services and technology; health care services; and business services and software.